Effectiveness of Routine BCG Vaccination on Buruli Ulcer Disease: A Case-Control Study in the Democratic Republic of Congo, Ghana and Togo

PLoS Neglected Tropical Diseases

Volumn 9, Issue 1, 2015, Pages

  Phillips, Richard Odame ^a   Phanzu, Delphin Mavinga ^b   Beissner, Marcus ^c   Badziklou, Kossi ^d   Luzolo, Elysée Kalundieko ^b   Sarfo, Fred Stephen ^a   Halatoko, Wemboo Afiwa ^d   Amoako, Yaw ^a   Frimpong, Michael ^e   Kabiru, Abass Mohammed ^f   Piten, Ebekalisai ^g   Maman, Issaka ^d   Bidjada, Bawimodom ^d   Koba, Adjaho ^d   Awoussi, Koffi Somenou ^d   Kobara, Basile ^d   Nitschke, Jörg ^c,h   Wiedemann, Franz Xaver ^h   Kere, Abiba Banla ^d   Adjei, Ohene ^a   Löscher, Thomas ^c   Fleischer, Bernhard ⁱ   Bretzel, Gisela ^c   Herbinger, Karl Heinz ^c   more..

^a KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^b Institut Médical Evangélique IME de Kimpese   (Congo)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Ministry of Health   (Togo)

^e KUMASI CENTRE FOR COLLABORATIVE RESEARCH IN TROPICAL MEDICINE   (Ghana)

^f Agogo Presbyterian Hospital   (Ghana)

^g Centre Hospitalier Régional Maritime CHR Maritime   (Togo)

^h Klinikum der Ludwig Maximilians Universität München   (Togo)

ⁱ BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BCG VACCINATION; BOVINE TUBERCULOSIS; BURULI ULCER; CASE CONTROL STUDY; CHILD; CLINICAL EFFECTIVENESS; CONGO; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GHANA; HEALING; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MYCOBACTERIUM BOVIS BCG; POLYMERASE CHAIN REACTION; PROGRAM EFFECTIVENESS; RETROSPECTIVE STUDY; SKIN SCAR; TOGO; ADOLESCENT; DEMOCRATIC REPUBLIC CONGO; EPIDEMIOLOGY; IMMUNOLOGY; INFANT; MIDDLE AGED; PRESCHOOL CHILD; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; BURULI ULCER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DEMOCRATIC REPUBLIC OF THE CONGO; FEMALE; GHANA; HUMANS; INFANT; MALE; MIDDLE AGED; RISK FACTORS; TOGO; YOUNG ADULT;

EID: 84922219971     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003457     Document Type: Article

References (63)

1. Merritt RW, Walker ED, Small PL, Wallace JR, Johnson PD, Benbow ME, Boakye DA, (2010) Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis 4 (12) e911.
2. I World Health Organization (2013) Buruli Ulcer (Mycobacterium ulcerans infection). Fact sheet N°199. Geneva: World Health Organization. Homepage http://www.who.int/mediacentre/factsheets/fs199/en/.
3. I Calmette A, Guérin C, Boquet A, Nègre L (1927) La vaccination préventive contre la tuberculose par le “BCG”. Masson, Paris.
4. Calmette A, Guérin C, Weill-Halle B, (1924) Bull Acad Med. Essai d'immunisation contre l'infection tuberculeuse 91: 787–96.
5. Luca S, Mihaescu T, (2013) History of BCG vaccine. Maedica 8 (1) 53–8.
6. II Calmette A, Guérin C, Nègre L, Boquet A, (1927) Sur la vaccination préventive des enfants nouveau-nés contre la tuberculose par le BCG. Ann Inst Pasteur 41: 201–32.
7. Moise L, McMurry J, de Groot AS, (2009) Mycobacterium tuberculosis. Barrett ADT, Stanberry LR (eds.): Vaccines for Biodefense and Emerging and Neglected Diseases. London, Elsevier 1219–1241.
8. Palmer CE, Long MW, (1966) Effects of Infection with Atypical Mycobacteria on BCG Vaccination and Tuberculosis. Am Rev Respir Dis 94 (4) 553–68.
9. Osborn TW, (1983) Changes in BCG strains. Tubercle 64 (1) 1–13.
10. Milstien JB, Gibson JJ, (1990) Quality Control of BCG Vaccine by WHO: a Review of Factors that May Influence Vaccine Effectiveness and Safety. Bull World Health Organ 68 (1) 93–108.
11. Hart PD, (1967) Efficacy and Applicability of Mass B.C.G. vaccination in tuberculosis control. BMJ 1 (5540) 587–92.
12. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F, (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271 (9) 698–702.
13. World Health Organization (1999) Issues relating to the use of BCG in immunization programmes: a discussion document. Publication No. WHO/V +13/99.23. Geneva: World Health Organization.
14. Debacker M, Portaels F, Aguiar J, Steunou C, Zinsou C, Meyers W, Dramaix M, (2006) Risk factors for Buruli ulcer, Benin. Emerg Infect Dis 12 (9) 1325–31.
15. Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N, (2008) Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev 32 (5) 821–41.
16. Behr MA, Small PM, (1999) A historical and molecular phylogeny of BCG strains. Vaccine 17 (7–8) 915–22.
17. Clements CJ, (2003) Vaccination – The Current Status of BCG. Kaufmann SHE, Hahn H (eds.): Mycobacteria and TB. Issues Infect Dis. Basel, Karger 2: 46–66.
18. Smith KC, Starke JR, (2012) Bacille Calmette-Guérin Vaccine. Plotkin SA, Orenstein W, Offit PA (eds.): Vaccines. Saunders 6: 188–209.
19. Ritz N, Dutta B, Donath S, Casalaz D, Connell TG, Tebruegge M, Robins-Browne R, Hanekom WA, Britton WJ, Curtis N, (2012) The influence of bacilli Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trail. Am J Respir Crit Care Med 185 (2) 213–22.
20. Merle CS, Cunha SS, Rodrigues LC, (2010) BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 13 (2) 209–22.
21. Setia MS, Steinmaus C, Ho CS, Rutherford GW, (2006) The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect 13 (3) 162–70.
22. Richardus RA, Alam K, Pahan D, Feenstra SG, Geluk A, Richardus JH, (2013) The combined effect of chemoprophylaxis with single dose rifampicin and immunoprophylaxis with BCG to prevent leprosy in contacts of newly diagnosed leprosy cases: a cluster randomized controlled trial (MALTALEP study). BMC Infect Dis 13: 456.
23. Richardus JH, Oskam L, (2015) Protecting people against leprosy: Chemoprophylaxis and Immunoprophylaxis. Clin Dermatol 33 (1) 19–25.
24. Uganda Buruli group (1969) BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda. Lancet 1 (7586) 111–5.
25. Smith PG, Revill WD, Lukwago E, Rykushin YF, (1976) The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R Soc Trop Med Hyg 70 (5–6) 449–57.
26. Portaels F, Aguiar J, Debacker M, Steunou C, Zinsou C, et al. (2002) Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli ulcer). Clin Diagn Lab Immunol 9 (6) 1389–91.
27. Portaels F, Aguiar J, Debacker M, Guédénon A, Steunou C, et al. (2004) Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 72 (1) 62–5.
28. Noeske J, Kuaban C, Rondini S, Sorlin P, Ciaffi L, et al. (2004) Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg 70 (5) 520–6.
29. Tanghe A, Content J, Van Vooren JP, Portaels F, Huygen K, (2001) Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun 69 (9) 5403–11.
30. Tanghe A, Adnet PY, Gartner T, Huygen K, (2007) A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice. Infect Immun 75 (5) 2642–4.
31. Fraga AG, Martins TG, Torrado E, Huygen K, Portaels F, et al. (2012) Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination. PLoS One 7 (3) e33406.
32. Nackers F, Dramaix M, Johnson RC, Zinsou C, Robert A, et al. (2006) BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin. Am J Trop Med Hyg 75 (4) 768–74.
33. Amofah GK, Sagoe-Moses C, Adjei-Acquah C, Frimpong EH, (1993) Epidemiology of Buruli ulcer in Amansie West district, Ghana. Trans R Soc Trop Med Hyg 87 (6) 644–5.
34. Raghunathan PL, Whitney EA, Asamoa K, Stienstra Y, Taylor TH, jret al. (2005) Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. Clin Infect Dis 40 (10) 1445–53.
35. CORDIS, Community Research and Development Information Service of the European Commission Seventh Framework Programme (FP7). Homepage http://cordis.europa.eu/fp7/home_en.html.
36. II World Health Organization (2013) Recommendations for Routine Immunization – Summary of WHO Position Papers. Homepage http://www.who.int/immunization/policy/Immunization_routine_table3.pdf.
37. III World Health Organization (2013) WHO-UNICEF estimates of BCG coverage WHO. Homepage http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragebcg.html.
38. Phanzu DM, Bafende EA, Dunda BK, Imposo DB, Kibadi AK, et al. (2006) Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002–2004. Am J Trop Med Hyg 75 (2) 311–4.
39. Phanzu DM, Suykerbuyk P, Imposo DB, Lukanu PN, Minuku JB, et al. (2011) Effect of a control project on clinical profiles and outcomes in buruli ulcer: a before/after study in Bas-Congo, Democratic Republic of Congo. PLoS Negl Trop Dis 5 (12) e1402.
40. Phillips R, Horsfield C, Kuijper S, Lartey A, Tetteh I, et al. (2005) Sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans in an Assay using punch biopsy specimens for diagnosis of Buruli ulcer. J Clin Microbiol 43 (8) 3650–6.
41. Schunk M, Thompson W, Klutse E, Nitschke J, Opare-Asamoah K, et al. (2009) Outcome of patients with buruli ulcer after surgical treatment with or without antimycobacterial treatment in Ghana. Am J Trop Med Hyg 81 (1) 75–81.
42. Bretzel G, Huber KL, Kobara B, Beissner M, Piten E, et al. (2011) Laboratory confirmation of Buruli ulcer disease in Togo, 2007–2010. PLoS Negl Trop Dis 7: e1228.
43. Beissner M, Huber KL, Badziklou K, Halatako WA, Maman I, et al. (2013) Implementation of a national reference laboratory for Buruli ulcer disease in Togo. PLoS Negl Trop Dis 7 (1) e2011.
44. World Health Organization (2008) Buruli ulcer: progress report, 2004–2008. Wkly Epidemiol Rec 83 (17) 145–54.
45. Fine PE, Ponnighaus JM, Maine N, (1989) The distribution and implications of BCG scars in northern Malawi. Bull World Health Organ 67 (1) 35–42.
46. Floyd S, Ponnighaus JM, Bliss L, Warndorff DK, Kasunga A, Mogha P, et al. (2000) BCG scar in northern Malawi: sensitivity and repeatability of scar reading, and factors affecting scar size. Int J Tuberc Lung Dis 4 (12) 1133–42.
47. Roth A, Sodemann M, Jensen H, Poulsen A, Gustafson P, et al. (2005) Vaccination. Vaccination technique, PPD reaction and BCG scarring in a cohort of children born in Guinea-Bissau 2000–2002. Vaccine 23 (30) 3991–8.
48. IV World Health Organization (2013) Guidance on sampling techniques for laboratory-confirmation of Mycobacterium ulcerans infection. Homepage http://www.who.int/buruli/Guidance_sampling_techniques_MU_infection.pdf.
49. Bretzel G, Siegmund V, Nitschke J, Herbinger KH, Thompson R, et al. (2006) External quality assurance for the laboratory diagnosis of Buruli ulcer disease in Ghana. Trop Med Int Health 11 (11) 1688–93.
50. Siegmund V, Adjei O, Nitschke J, Thompson W, Klutse E, et al. (2007) Dry reagent-based polymerase chain reaction compared with other laboratory methods available for the diagnosis of Buruli ulcer disease. Clin Infect Dis 45 (1) 68–75.
51. Bretzel G, Siegmund V, Nitschke J, Herbinger KH, Thompson W, et al. (2007) A stepwise approach to the laboratory diagnosis of Buruli ulcer disease. Trop Med Int Health 12 (1) 89–96.
52. I Herbinger KH, Brieske D, Nitschke J, Siegmund V, Thompson W, et al. (2009) Excision of pre-ulcerative forms of Buruli Ulcer Disease: A curative treatment? Infection 37 (1) 20–5.
53. II Herbinger KH, Adjei O, Awua-Boateng NY, Nienhuis WA, Kunaa L, et al. (2009) Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin Infect Dis 48 (8) 1055–64.
54. Eddyani M, Fraga AG, Schmitt F, Uwizeye C, Fissette K, et al. (2009) Fine needle aspiration, an efficient sampling technique for the bacteriological diagnosis of nonulcerative Buruli ulcer lesions. J Clin Microbiol 47 (6) 1700–4.
55. Phillips RO, Sarfo FS, Osei-Sarpong F, Boateng A, Tetteh I, et al. (2009) Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer. J Clin Microbiol 47 (4) 924–6.
56. Herbinger KH, Beissner M, Huber K, Awua-Boateng NY, Nitschke J, et al. (2010) Efficiency of fine-needle aspiration compared with other sampling techniques for laboratory diagnosis of Buruli ulcer disease. J Clin Microbiol 48 (10) 3732–4.
57. World Health Organization (2010) Guidance on sampling techniques for laboratory-confirmation of Mycobacterium ulcerans infection (Buruli ulcer disease). Geneva: World Health Organization.
58. World Health Organization (2001) Diagnosis of Mycobacterium ulcerans disease. Geneva: World Health Organization.
59. Beissner M, Herbinger KH, Bretzel G, (2010) Laboratory diagnosis of Buruli ulcer disease. Future Microbiol 5 (3) 363–70.
60. Siegmund V, Adjei O, Racz P, Berberich C, Klutse E, et al. (2005) Dry-reagent-based PCR as a novel tool for laboratory confirmation of clinically diagnosed Mycobacterium ulcerans-associated disease in areas in the tropics where M. ulcerans is endemic. J Clin Microbiol 43 (1) 271–6.
61. Fyfe JA, Lavender CJ, Johnson PD, Globan M, Sievers A, et al. (2007) Development and application of two multiplex real-time PCR assays for the detection of Mycobacterium ulcerans in clinical and environmental samples. Appl Environ Microbiol 73 (15) 4733–40.
62. Beissner M, Symank D, Phillips RO, Amoako YA, Awua-Boateng NY, et al. (2012) Detection of Viable Mycobacterium ulcerans in Clinical Samples by a Novel Combined 16S rRNA Reverse Transcriptase/IS2404 Real-Time qPCR Assay. PLoS Negl Trop Dis 6 (8) e1756.
63. Comstock GW, (1988) Identification of an effective vaccine against tuberculosis. Am Rev Respir Dis 138 (2) 479–80.a.